Prognostic value of immunotherapy in advanced NSCLC based on baseline and dynamic changes in HALP
2025

Prognostic Value of Immunotherapy in Advanced NSCLC

Sample size: 203 publication Evidence: high

Author Information

Author(s): Su Hui, Yu Chao, Sun Guiming, Wang Baozhong, Gao Yingjie, Liu Xiaolan, Ma Xuezhen

Primary Institution: Department of Oncology, Medical College of Qingdao University, Qingdao, China

Hypothesis

This study aims to explore the clinical significance of baseline and dynamic changes in HALP, NLR, and PLR values for predicting prognosis in NSCLC patients.

Conclusion

The HALP, NLR, and PLR values effectively predicted the response to immunotherapy in patients with advanced NSCLC, with low HALP combined with high NLR and PLR indicating a poor prognosis.

Supporting Evidence

  • HALP, NLR, and PLR values at various time points effectively predicted immunotherapy response in advanced NSCLC patients.
  • Low HALP combined with high NLR and PLR values was associated with poor prognosis.
  • The C-indices for PFS and OS were 0.823 and 0.878, indicating good predictive accuracy.
  • Multivariate Cox analysis showed that age ≥65 years and low HALP were significant predictors of worse outcomes.

Takeaway

Doctors can use simple blood tests to help figure out how well treatment will work for lung cancer patients. If the tests show low HALP and high NLR and PLR, it might mean the patient will not do well.

Methodology

Clinical and hematological data from NSCLC patients who received immunotherapy were analyzed, and prediction models were developed based on HALP, NLR, and PLR values.

Potential Biases

The lack of a chemotherapy-only control group makes it difficult to differentiate the specific effects of immunotherapy on the hematological markers studied.

Limitations

The study was a single-center, retrospective study with a limited sample size, which may affect the generalizability of the results.

Participant Demographics

{"male_percentage":77.83,"female_percentage":22.17,"age_below_65_percentage":48.77,"age_above_65_percentage":51.23,"smoking_percentage":63.05,"drinking_percentage":36.45,"ecog_ps_0_1_percentage":91.63,"ecog_ps_2_percentage":8.37,"stage_iii_percentage":42.86,"stage_iv_percentage":57.14}

Statistical Information

Confidence Interval

95% CI: 0.799–0.848 for PFS, 95% CI: 0.845–0.912 for OS

Statistical Significance

p<0.05

Digital Object Identifier (DOI)

10.17305/bb.2024.10833

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication